• Anifrolumab Shows Benefit in Patients with Systemic Lupus Erythematosus americanpharmaceuticalreview
    June 04, 2021
    A new post-hoc analysis of pooled data from the TULIP Phase III clinical trials being presented at the annual European Congress of Rheumatology (EULAR 2021) showed anifrolumab was consistently associated with improvements in both skin rash and ...
PharmaSources Customer Service